Pet owner compliance is essential for the success of veterinary healthcare strategies. As some parasites are zoonotic, consistent parasite control is an integral part of the One-Health strategy. Highly palatable formu...Pet owner compliance is essential for the success of veterinary healthcare strategies. As some parasites are zoonotic, consistent parasite control is an integral part of the One-Health strategy. Highly palatable formulations help ensure compliance, as they offer a positive experience for the dog and the owner. This study was conducted to ascertain if dogs exhibited a preference between two commercially available oral formulations of broad-spectrum endectoparasiticides, NexGard Spectra (afoxolaner and milbemycin oxime) and Simparica Trio (sarolaner, moxidectin and pyrantel). For four consecutive days, 100 healthy dogs were offered both products and consumption was recorded. If one product was more consumed than the other, it was defined as the preferred product. No adverse event was recorded throughout the study. A total of 358 chewable tablets were consumed over four study days;78.5% of dogs voluntarily consumed NexGard Spectra (281 chews), while 21.5% of dogs voluntarily consumed Simparica Trio (77 chews, <i>p</i> < 0.01). Among 75 dogs which demonstrated a preference for a product, significantly more dogs preferred NexGard Spectra (94.7%) compared to Simparica Trio (5.3%) (<i>p</i> < 2.2 × 10<sup>-16</sup>), resulting in a preference ratio of 17.75 to 1 for NexGard Spectra.展开更多
文摘Pet owner compliance is essential for the success of veterinary healthcare strategies. As some parasites are zoonotic, consistent parasite control is an integral part of the One-Health strategy. Highly palatable formulations help ensure compliance, as they offer a positive experience for the dog and the owner. This study was conducted to ascertain if dogs exhibited a preference between two commercially available oral formulations of broad-spectrum endectoparasiticides, NexGard Spectra (afoxolaner and milbemycin oxime) and Simparica Trio (sarolaner, moxidectin and pyrantel). For four consecutive days, 100 healthy dogs were offered both products and consumption was recorded. If one product was more consumed than the other, it was defined as the preferred product. No adverse event was recorded throughout the study. A total of 358 chewable tablets were consumed over four study days;78.5% of dogs voluntarily consumed NexGard Spectra (281 chews), while 21.5% of dogs voluntarily consumed Simparica Trio (77 chews, <i>p</i> < 0.01). Among 75 dogs which demonstrated a preference for a product, significantly more dogs preferred NexGard Spectra (94.7%) compared to Simparica Trio (5.3%) (<i>p</i> < 2.2 × 10<sup>-16</sup>), resulting in a preference ratio of 17.75 to 1 for NexGard Spectra.
